# US 8,277,814 B2 · Avian Astrovirus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,277,814 B2 - Document ID: US8277814B2 - Status: Granted - Kind: B2 - Application number: 12/989,865 - Filed: 2009-04-27 - Published: 2011-05-05 - Granted: 2012-10-02 - Earliest claimed: 2008-04-28 - Assignees: Intervet International B.V. - Inventors: Sjaak De Wit; Carla Christina Schrier; Marcel Van de Laar; Iwan Verstegen - Web page: https://patentgrep.com/patent/US8277814B2 ## CPC - C07K 14/005: from viruses - A61P 31/04: Antibacterial agents - A61P 31/14: for RNA viruses - A61P 37/04: Immunostimulants - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - A61K 2039/525: {Virus} - C12N 2770/12021: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2770/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2770/12051: Methods of production or purification of viral material - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention relates to the fields of veterinary virology and immunology. In particular the invention relates to a novel avian Astrovirus; to antibodies or fragments thereof against the novel virus; to antigenic preparations, proteins, and DNA molecules of the novel avian Astrovirus; to vaccines of the novel virus or its antigenic preparations, protein, or DNA; to methods for the manufacture of such vaccines, and to diagnostic kits. ## Claims ### Claim 1 An isolated Avian Astrovirus having an open reading frame (ORF) 1a genomic region, characterised in that the ORF1a of said avian Astrovirus, when compared to the ORF 1a of avian nephritis virus 1, contains an insert of 12 nucleotides, said insert being located in between nucleotides corresponding to the nucleotides numbered 2485 and 2486 of SEQ ID NO: 1. ### Claim 2 (depends on 1) The isolated Avian Astrovirus according to claim 1, characterised in that the insert of 12 nucleotides has a nucleic acid sequence as presented in SEQ ID NO: 2. ### Claim 3 (depends on 1) The isolated Avian Astrovirus according to claim 1, characterised in that the ORF 1a of said avian Astrovirus comprises a region having a nucleotide sequence identity of at least 88% with SEQ ID NO: 4. ### Claim 4 (depends on 1) The isolated Avian Astrovirus according to claim 1, characterised in that from the ORF 1a of said avian Astrovirus a PCR product of about 260 nucleotides can be produced in a PCR-assay using a set of the primers represented in SEQ ID NO: 30 and SEQ ID NO: 31. ### Claim 5 (depends on 1) The isolated Avian Astrovirus according to claim 1, which is a virus as deposited under number CNCM I-3895 at the Collection Nationale de Cultures de Micro-organismes (CNCM), of the Institut Pasteur in Paris, France. ### Claim 6 An isolated DNA molecule comprising a region having a nucleotide sequence identity of at least 88% with SEQ ID NO: 4. ### Claim 7 An isolated protein comprising a region having an amino acid sequence identity of at least 93% with SEQ ID NO: 5. ### Claim 8 (depends on 1) A vaccine comprising the isolated avian Astrovirus according to claim 1 and a pharmaceutically acceptable carrier. ### Claim 9 (depends on 8) The vaccine according to claim 8, comprising at least one additional antigen obtainable from a micro-organism pathogenic to poultry. ### Claim 10 (depends on 1) An immunogenic composition for inducing an immune response in poultry, comprising the isolated avian Astrovirus according to claim 1. ### Claim 11 (depends on 1) A method for manufacturing a vaccine for poultry comprising mixing an appropriate pharmaceutical carrier and the isolated avian Astrovirus according to claim 1. ### Claim 12 (depends on 1) A diagnostic kit comprising the isolated avian Astrovirus according to claim 1. ### Claim 13 (depends on 6) A vaccine comprising the DNA molecule according to claim 6 and a pharmaceutically acceptable carrier. ### Claim 14 (depends on 7) A vaccine comprising the protein according to claim 7 and a pharmaceutically acceptable carrier.